Death and competition cause Exelixis dive on positive cabozantinib data in solid cancers
This article was originally published in Scrip
Executive Summary
Exelixis, which has put everything behind its lead anticancer product cabozantinib, closed 20% down on 6 June at $8.69 after the US company reported data from a Phase II trial showing that cabozantinib caused the deaths of six patients in a Phase II trial in patients with advanced solid tumours. The company now expects to begin a phase III study before the end of 2011.